Evidence map›Paper›PMID 26268784›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.

Julie Vanbockstael, Elodie Coquan, Sophie Gouerant, Djelila Allouache, Audrey Faveyrial, Sabine Noal, Corinne Delcambre, Marie-Pierre Galais, Jean-François Héron, Anne-Charlotte Lefebvre and 14 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Beyond current aprepitant evidence: room for improvement on dose selection and chemotherapy-induced nausea and vomiting risk factors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 1 country.

Julie VanbockstaelCentre François Baclesse, Department of Oncology, Caen, France.
Elodie CoquanCentre François Baclesse, Department of Oncology, Caen, France. e.coquan@baclesse.unicancer.fr.
Sophie GouerantRouen University Hospital, Department of Oncology, Rouen, France.
Djelila AllouacheCentre François Baclesse, Department of Oncology, Caen, France.
Audrey FaveyrialCentre François Baclesse, Department of Oncology, Caen, France.
Sabine NoalCentre François Baclesse, Department of Oncology, Caen, France.
Corinne DelcambreCentre François Baclesse, Department of Oncology, Caen, France.
Marie-Pierre GalaisCentre François Baclesse, Department of Oncology, Caen, France.
Jean-François HéronCentre François Baclesse, Department of Oncology, Caen, France.
Anne-Charlotte LefebvreCentre François Baclesse, Department of Oncology, Caen, France.
Emmanuel SevinCentre François Baclesse, Department of Oncology, Caen, France.
Ioana HrabCentre François Baclesse, Department of Oncology, Caen, France.
Florence PolycarpeCentre François Baclesse, Department of Oncology, Caen, France.
Michel AndréHôpital Monod, Department of Oncology, Flers, France.
Laure KaluzinskiCentre Hospitalier Public du Cotentin, Department of Oncology, Cherbourg-Octeville, France.
Radj GervaisCentre François Baclesse, Department of Oncology, Caen, France.
Katharina GunzerCentre François Baclesse, Department of Oncology, Caen, France.
Brigitte ViéClinique Armoricaine, Department of Oncology, Saint-Brieuc, France.
Gilles SaucierHôpital Monod, Department of Oncology, Flers, France.
Noëmie LemenandCentre François Baclesse, Clinical Research Department, av général Harris, Caen, 14000, France.
Jean-Michel GrellardCentre François Baclesse, Clinical Research Department, av général Harris, Caen, 14000, France.
Bénédicte ClarisseCentre François Baclesse, Clinical Research Department, av général Harris, Caen, 14000, France.
Audrey Emmanuelle DuguéCentre François Baclesse, Clinical Research Department, av général Harris, Caen, 14000, France.
Florence JolyCentre François Baclesse, Clinical Research Department, av général Harris, Caen, 14000, France.
Centre François Baclesse · FRCentre Hospitalier de Saint-Brieuc · FRCentre Hospitalier Public du Cotentin · FRCentre Virchow-Villermé · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemotherapy-induced nausea and vomiting (CINV) still remain frequent. The procedure for announcing the diagnosis (PAD) was an emblematic measure of the first French Plan Cancer aiming at providing patients with time to listen, information after cancer diagnosis, and discussion on treatments and their side effects. We aimed at assessing the risk factors of CINV, focusing on patients' satisfaction with the PAD.

methodsThis prospective multicentre study assessed the frequency and intensity of CINV among chemonaïve patients during the first cycle of treatment. CINV was defined by ≥1 emetic episode or reported nausea intensity ≥3 on a 0-10 scale. Multivariate analysis was used to identify factors related to global CINV onset including satisfaction with the PAD (satisfaction score ≥the median on a 0-10 scale).

resultsData from 291 patients (women, 85.2%; mean age, 57 years) were analyzed. Most patients (69.4%) received highly emetogenic chemotherapy regimens and 77.7% received antiemetic drugs consistent with international guidelines. Acute, delayed and overall CINV were experienced by 40.4, 34.8 and 52.4% of patients, respectively. Sixty-seven per cent of patients were satisfied with the PAD. No relation was noted between PAD satisfaction and CINV onset. The nausea and vomiting dimension of the QLQ-C30 questionnaire before chemotherapy (OR 3.62), motion sickness history (OR 2.73), highly emetogenic CT (OR 2.73), anxiety (OR 1.99) and younger age (OR 1.96) were independent predictive factors.

conclusionsAlthough patients were mostly satisfied with the PAD, half of them experienced CINV. A state of anxiety could be identified during the PAD to be managed.

Indexed as

AntiemeticsAntineoplastic AgentsFemaleFranceHumansMaleMiddle AgedNauseaNeoplasmsProspective StudiesVomitingAntiemeticsAntineoplastic AgentsCancer announcementChemotherapy-induced nausea and vomitingNauseaVomiting

Identifiers

PMID26268784
OpenAlexW1123195881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.